Capecitabine Tablet, Film Coated
Product Images NDC 72603-303

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 72603-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabinechemicalstructure (Capecitabinechemicalstructure)

Chemical structure of capecitabine, showing its molecular composition including fluorine, oxygen, nitrogen, carbon, hydrogen, and sulfur atoms arranged in multiple rings and chains.*

FDA Label Image

Capecitabinefigure1 (Capecitabinefigure1)

A Kaplan-Meier survival curve graph comparing two treatment groups: 5-FU + leucovorin (dashed line) and capecitabine (solid line). The x-axis shows months since randomization (0 to 96 months), and the y-axis shows survival probability (0 to 1). Numbers at risk for both treatment groups are listed below the x-axis over time.*

FDA Label Image

Capecitabinefigure2 (Capecitabinefigure2)

A survival curve chart comparing two treatment groups: 5-FU + Leucovorin and Capecitabine over a period of 96 months since randomization. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows time in months. Below the chart, the number of patients at risk in each group is listed at various time points.*

FDA Label Image

Capecitabinefigure3 (Capecitabinefigure3)

A survival curve chart comparing two treatment groups: '5-FU + Leucovorin (Mayo Regimen)' and 'Capecitabine 1250 (mg/sqm twice daily) intermittent.' The x-axis represents time in days, ranging from 0 to 1500, and the y-axis represents the estimated probability, ranging from 0 to 1. The chart shows declining survival probabilities over time for both groups, with a marked point around 391-392 days.*

FDA Label Image

Capecitabinefigure4 (Capecitabinefigure4)

A survival curve graph comparing two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The estimated probability is plotted on the vertical axis and time in days on the horizontal axis. Arrows mark specific time points at 128 and 186 days.*

FDA Label Image

Capecitabinefigure5 (Capecitabinefigure5)

A Kaplan-Meier survival curve showing estimated probability over time in days, comparing two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The graph features probability on the Y-axis and time in days on the X-axis, with survival lines and noted median survival times indicated by arrows.*

FDA Label Image

Capecitabinetablets500mg120s (Capecitabinetablets500mg120s)

Label for Capecitabine Tablets USP 500 mg, film-coated tablets in a bottle of 120 count. The label states it is a hazardous drug and cytotoxic agent. Manufactured for NorthStar Rx LLC, Memphis, TN and made by Hetero Labs Limited, India. Includes storage instructions and usage warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.